In Taiwan, drug patents are managed under a patent linkage system, ensuring that generic drug approval is aligned with patent protections. During registration, innovators list patents with the TFDA, and generics cannot be approved until the patents expire or are legally challenged. This system promotes innovation while balancing market competition.